Glenmark Generics Inc, a subsidiary of Glenmark, has received approval from US Food and Drug Administration (USFDA) for Zolmitriptan tablets and Zolmitriptan Orally Disintegrating tablets, Glenmark said in a statement.
"Glenmark will commence distribution of the product immediately," the Mumbai-based firm said.
Also Read
According to IMS Health, for the 12-month period ended December 2012, the products garnered annual sales of $176 million.
Glenmark's current portfolio consists of 85 products authorised for distribution in the US market.
Shares of Glenmark were trading at Rs 555 on the BSE in late afternoon trade, up 1.34% from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)